Showing results (321-330 of 339) with videos related to

Sort By:
Pageof 34
Med (New York, N.Y.)|November 11, 2023
Transforming ovarian cancer care by targeting minimal residual diseaseAmir A Jazaeri, Rachel Grisham, Anne Knisely, et al.
ESMO Open|July 22, 2026
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trialsB A Maiorano, M Maruzzo, A Ślusarczyk, et al.
Actas Urologicas Espanolas|February 14, 2025
The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic reviewE Albers Acosta, L Pelari-Mici, G Celada Luis, et al.
Nature Communications|May 20, 2020
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.
Nature Communications|March 21, 2020
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerA G Waks, O Cohen, B Kochupurakkal, et al.
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Nature Genetics|August 22, 2017
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancerPaz Polak, Jaegil Kim, Lior Z Braunstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Hanrong Feng, Kalindi Parmar, et al.
Pageof 34